ERBB2 and neoplasm: At last, we chose the proposed modification by Ruschoff et al. for assessing Her2 on biopsies [20] for the immunohistochemical evaluation of Her2 on three TMA cores for each tumor, as we did in our previous study on esophageal adenocarcinomas, which show similar degrees of intratumoral heterogeneity of Her2 [21,35,36].